United States In Vivo Toxicology Market to Reach US$ 7.8 Billion by 2031, Driven by Rising Demand for Advanced Preclinical Safety Testing- Exclusive Report by DatamIntelligence

Leander, Texas and TOKYO, Japan - Nov. 26. 2025 "In Vivo Toxicology Market is anticipated to grow at high CAGR during the forecast period 2024-2031."

The In Vivo Toxicology Market is driven by rising demand for safety assessment of pharmaceuticals, chemicals, and consumer products before clinical or commercial use. Market growth is supported by increasing R&D activities, regulatory requirements for toxicity testing, and advancements in animal models and analytical techniques to evaluate drug efficacy and potential adverse effects.

➠ Download Your Sample Report Instantly - Corporate Email ID Required for Priority Access: https://www.datamintelligence.com/download-sample/in-vivo-toxicology-market?praneetha

☛ Recent Industry Developments :
United States:
✅ November 2025: Charles River Laboratories launched a next-generation in vivo toxicology platform integrating AI-driven dose prediction, supported by 110 million in technology upgrades. The innovation enhances preclinical safety testing accuracy for pharma and biotech companies.

✅ October 2025: Labcorp Drug Development completed the acquisition of a U.S. based specialty toxicology CRO, investing 82 million to expand its nonclinical safety assessment capabilities. The deal strengthens Labcorp's portfolio in genetic, reproductive, and chronic toxicity studies.

✅ September 2025: Thermo Fisher Scientific introduced a new in vivo immunotoxicity testing solution, backed by 56 million in R&D investment. The system accelerates biologics and gene therapy safety evaluations using enhanced biomarker detection methods.

Japan:
✅ November 2025: Shin Nippon Biomedical Laboratories (SNBL) launched an upgraded in vivo toxicity assessment facility with 38 million invested in advanced imaging and behavioral monitoring systems. The expansion supports Japan's rising demand for high precision nonclinical testing.

✅ October 2025: Fuji Pharma completed the acquisition of a local toxicology service provider, allocating 27 million to enhance early stage drug safety evaluation pipelines. The move strengthens Japan's domestic preclinical infrastructure for new drug development.

✅ September 2025: Takeda Pharmaceutical partnered with a Japanese research institute to launch a next-gen zebrafish based in vivo toxicity screening platform, supported by 21 million in joint funding. The initiative aims to accelerate toxicity prediction for small molecules and biologics.

☛ Core Catalysts Behind Market Growth:
Rising prevalence of chronic diseases and increasing demand for new therapeutics are driving the need for in vivo toxicology studies to ensure drug safety and regulatory compliance.

Growing R&D investments by pharmaceutical, biotechnology, and chemical companies are accelerating the adoption of animal based toxicity testing.

Advancements in imaging technologies, biomarkers, and genetically modified animal models are improving study accuracy, speed, and predictive value.

Stringent global safety regulations and the need to assess environmental, chemical, and consumer product toxicity are further boosting market growth across research institutions and CROs.

➠ Get Customization in the Report as per Your Requirements:
https://www.datamintelligence.com/customize/in-vivo-toxicology-market?praneetha

☛ Market Segmentation:
By Product Type:
Kits lead with 40% share, driven by their standardized protocols, ease of use, and wide adoption in toxicity screening workflows across pharma and biotech.

Reagents hold 30% share, growing due to increasing demand for reliable chemicals and consumables in preclinical testing.

Equipments account for 20% share, supported by rising use of imaging systems, analytical devices, and automated testing platforms.

Other products capture 10% share, including accessories, consumables, and supporting lab materials.

By Test Type:
Subchronic Toxicity Tests dominate with 35% share, favored for intermediate duration studies that inform dose response and safety evaluation.

Chronic Toxicity Tests hold 25% share, used for long term exposure studies, especially in drug development and regulatory submissions.

Carcinogenicity Tests account for 20% share, critical for assessing cancer risk potential in pharmaceuticals and chemicals.

Other test types capture 20% share, including reproductive toxicity, developmental toxicity, and specialized safety assessments.

By Technology :
In Vivo Imaging leads with 38% share, driven by advances in MRI, PET, CT, and optical imaging for non invasive monitoring of toxicity.

In Silico Models hold 25% share, growing rapidly as computational toxicology and AI-based predictive modeling gain adoption.

Omics Technologies account for 22% share, including genomics, proteomics, and metabolomics for mechanism based toxicity studies.

Other technologies capture 15% share, covering hybrid approaches, microfluidics, and emerging preclinical platforms.

By End User :
Pharmaceutical and Biotechnology Companies dominate with 45% share, as they conduct preclinical safety testing to comply with regulatory requirements.

Contract Research Organizations (CROs) hold 30% share, expanding due to outsourcing trends in drug development and increasing preclinical demand.

Academic and Research Institutions account for 15% share, leveraging in vivo models for fundamental research and translational studies.

Other end-users capture 10% share, including government labs, toxicology service providers, and specialty research centers.

☛ Competitive Landscape :
The market is characterized by intense competition among global contract research organizations (CROs), pharmaceutical testing laboratories, and specialized toxicology solution providers.

Charles River Laboratories - Leads the global market with an estimated 20% share, offering comprehensive in vivo toxicology testing services, preclinical research solutions, and regulatory compliant study designs.

Merck KGaA - Holds approximately 18% market share, providing advanced toxicology platforms, in vivo models, and integrated bioanalytics for pharmaceutical and biotech companies.

Eurofins Scientific - Captures around 15% of the market, leveraging its global laboratory network to deliver preclinical toxicology testing, ADME studies, and safety assessment services.

Labcorp Drug Development - Commands close to 13% market share, offering specialized in vivo toxicology studies, safety pharmacology, and regulatory support for drug development pipelines.

PerkinElmer Inc. - Maintains roughly 12% market share through its innovative imaging systems, preclinical testing solutions, and in vivo research platforms for toxicology and pharmacology applications.

Other Key Players: MATTEK CORPORATION, Vimta Labs Ltd, NUVISAN GmbH, Nagi Bioscience, Taconic Biosciences.

➠ Purchase this report before year-end and unlock an exclusive 30% discount:

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=in-vivo-toxicology-market?praneetha
(Purchase 2 or more Reports and get 50% Discount)

☛ Regional Analysis:
North America:
North America leads the market with 38%, driven by strong pharmaceutical R&D spending, extensive preclinical testing infrastructure, and stringent regulatory requirements from the FDA. The U.S. dominates due to the presence of major biotech companies, CROs, and academic research centers performing toxicology studies for drug discovery and safety assessment.

Europe:
Europe holds 28%, supported by well established drug development frameworks, strong academic research, and advanced toxicology testing facilities in Germany, the U.K., France, Switzerland, and Italy. Growing focus on chemical safety, REACH compliance, and biomedical innovation enhances regional demand.

Asia Pacific:
Asia Pacific accounts for 24%, fueled by rapid expansion of pharmaceutical manufacturing, increasing outsourcing to CROs in China and India, and growing investments in biomedical research. Rising preclinical activity in Japan and South Korea further accelerates growth.

Latin America:
Latin America holds 5%, with demand primarily from Brazil, Mexico, and Argentina. Growth is driven by an expanding pharmaceutical sector and increasing collaborations with global research organizations, although limited advanced infrastructure constrains faster adoption.

Middle East:
The Middle East accounts for 3%, with emerging demand in the UAE, Saudi Arabia, and Israel. Investments in biomedical research, clinical development, and laboratory modernization support gradual market expansion.

Africa:
Africa holds 2%, with activity concentrated in South Africa and Egypt. Limited R&D infrastructure and funding restrict market growth, although increasing participation in global research collaborations offers future opportunities.

➠ Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Market Access Snapshots
✅ Emerging Risks & Market Volatility Analysis
✅ Quarterly Updated Reports
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Company Name: DataM Intelligence 4Market Research LLP
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com/

DataM Intelligence is a global Market Research and Consulting firm providing comprehensive business insights and end-to-end solutions from research to consulting. We deliver actionable intelligence across 6,300+ reports spanning 40+ domains, empowering over 200 companies in 50+ countries. Our focus is on enabling clients to make data-driven decisions through robust methodologies, strategic foresight, and real-time market intelligence.

This release was published on openPR.